Zobrazeno 1 - 10 of 143 pro vyhledávání: '"Steinar Aamdal"'
3
Akademický článek
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Autor: Elin Aamdal, Else Marit Inderberg, Espen Basmo Ellingsen, Wenche Rasch, Paal Fredrik Brunsvig, Steinar Aamdal, Karen-Marie Heintz, Daniel Vodák, Sigve Nakken, Eivind Hovig, Marta Nyakas, Tormod Kyrre Guren, Gustav Gaudernack
Publikováno v: Frontiers in Immunology, Vol 12 (2021)
BackgroundIpilimumab improves survival for patients with metastatic malignant melanoma. Combining a therapeutic cancer vaccine with ipilimumab may increase efficacy by providing enhanced anti-tumor immune responses. UV1 consists of three synthetic lo
Externí odkaz: https://doaj.org/article/38c8cf6e13884546a9eeb6e622910c9b
Zobrazit plný text záznamu
4
Akademický článek
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Autor: Paal F. Brunsvig, Tormod Kyrre Guren, Marta Nyakas, Claudius H. Steinfeldt-Reisse, Wenche Rasch, Jon Amund Kyte, Hedvig Vidarsdotter Juul, Steinar Aamdal, Gustav Gaudernack, Else Marit Inderberg
Publikováno v: Frontiers in Immunology, Vol 11 (2020)
Human telomerase reverse transcriptase (hTERT) is a target antigen for cancer immunotherapy in patients with non-small cell lung cancer (NSCLC). We have tested a novel hTERT vaccine, UV1, designed to give high population coverage. UV1 is composed of
Externí odkaz: https://doaj.org/article/41a6f845f5a44e1880c305a1ad02c3af
Zobrazit plný text záznamu
5
Akademický článek
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Autor: Mouldy Sioud, Marta Nyakas, Stein Sæbøe-Larssen, Anne Mobergslien, Steinar Aamdal, Gunnar Kvalheim
Publikováno v: Case Reports in Medicine, Vol 2016 (2016)
Indoleamine 2,3-dioxygenase (IDO) expression in dendritic cells (DCs) inhibits T-cell activation and promotes T-cell differentiation into regulatory T-cells. Moreover, IDO expression promotes resistance to immunotherapies targeting immune checkpoints
Externí odkaz: https://doaj.org/article/e405f936753c43219f659d34e32ad15d
Zobrazit plný text záznamu
6
Data from Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
Autor: Steinar Aamdal, Gustav Gaudernack, Gaute L. Hansen, Marta Nyakas, Mona Møller, Stein Sundstrøm, Christian Kersten, Jon Amund Kyte, Paal Fr. Brunsvig
Purpose: We report two clinical trials in non–small cell lung cancer (NSCLC) patients evaluating immune response, toxicity, and clinical outcome after vaccination with the telomerase peptide GV1001: a phase II trial (CTN-2006) in patients vaccinate
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92053c7cd6ee8c57c30433cfe21f1dba
https://doi.org/10.1158/1078-0432.c.6520149
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje